Immix Biopharma Inc（IMMX）财务数据IMMXImmix Biopharma Inc

Evaluating the bottom line, Immix Biopharma, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -34.18%, provide a clear picture of how effectively IMMX converts its operational activities into shareholder value.

In the context of the broader market, IMMX competes directly with industry leaders such as ACHV and LXRX. With a market capitalization of $740.24M, it holds a significant position in the sector. When comparing efficiency, IMMX's gross margin of N/A stands against ACHV's N/A and LXRX's 94.36%. Such benchmarking helps identify whether Immix Biopharma, Inc. is trading at a premium or discount relative to its financial performance.

The company has reported consistent net losses, with the latest quarterly net income at -11,557,002 USD, and a negative EPS of -0.18. However, the current ratio has improved significantly to 25.13, indicating strong liquidity.